Skip to main content

Table 1 Association analysis between FBI-1 expression and the clinicopathological features of ovarian cancers

From: Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers

  

Case assessed

Score

(mean ± SE)

p-value

Diagnostic categories

Benign

10

0

0.000a

 

Borderline

19

7.83 ± 0.92

0.000a, 0.000b

 

Primary cancer

111

12.31 ± 0.37

0.000a

 

Metastatic foci

63

13.47 ± 0.46

0.036c

 

Malignant ascites

17

14.11 ± 0.87

0.021c

Histological types of ovarian cancer

Serous

43

12.53 ± 1.04

0.070d

 

Endometrioid

36

11.82 ± 0.66

 
 

Clear cell

23

12.76 ± 0.53

 
 

Mucinous

9

12.11 ± 1.17

 

Stage

Stage I

42

11.30 ± 0.67

0.012e

 

Stage II-IV

69

13.38 ± 0.42

 

Grade

Low (grade I)

32

12.22 ± 0.73

0.151f

 

High (grade II and III)

79

12.39 ± 0.44

 

Response to primary chemotherapy

Sensitive

78

12.14 ± 0.45

0.246g

 

Resistant

18

13.22 ± 0.92

 

Survival months

0.53~188.57 (average: 44.7)

  1. a p Value reflects the comparison of each category vs. benign tumor.
  2. b p Value reflects the comparison of primary cancer vs. borderline.
  3. c p Value reflects the comparison of metastatic foci or malignant ascites versus primary cancer.
  4. d p Value reflects the comparison of clear cell carcinoma versus all the other histological types combined.
  5. e p Value reflects the comparison of stage I versus stage II-IV.
  6. f p Value reflects the comparison of low grade versus. high grade.
  7. g p Value reflects the comparison of chemosensitive versus chemoresistant.